Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Should we be applying warfarin pharmacogenetics to clinical practice? No, not now.

Annals of internal medicine - 18 Aug 2009

Rosove Michael H, Grody Wayne W

Abstract excerpt

The U.S. Food and Drug Administration modified warfarin labeling in 2007 to suggest, but not mandate, pharmacogenetic testing. Genetic analysis is now commercially available. However, results predict only one third of all dosing variation, the value of testing in reducing bleeding and thrombosis rates remains unproved, and cost-effectiveness is not established. Careful consideration of clinical factors that...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticoagulants
Share to Cost-Benefit Analysis
Share to Cytochrome P-450 CYP2C9

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hemorrhage

Share to Protein Array Analysis

Share to United States Food and Drug Administration

Share to Vitamin K Epoxide Reductases

Share to Warfarin

Source

Identifiers

PMID: 19687493
DOI: 10.7326/0003-4819-151-4-200908180-00009

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Should we be applying warfarin pharmacogenetics to clinical practice? No, not now.PMID 19687493Read ↗

Genotype-guided warfarin therapy: current status.Semantic proximity Read ↗

Warfarin Pharmacogenetic Trials: Is there a Future for Pharmacogenetic-Guided Dosing?Semantic proximity Read ↗

Using genetic testing to guide warfarin therapy.Semantic proximity Read ↗

Pharmacogenetics of warfarin: challenges and opportunitiesSemantic proximity Read ↗

Warfarin pharmacogenomics: recommendations with available patented clinical technologies.Semantic proximity Read ↗

Role of Warfarin Pharmacogenetic Testing in Clinical PracticeSemantic proximity Read ↗

A regulatory science perspective on warfarin therapy: a pharmacogenetic opportunity.Semantic proximity Read ↗

Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues.Semantic proximity Read ↗

Pharmacogenetic-based dosing of warfarin.Semantic proximity Read ↗

Warfarin pharmacogenetics: to genotype or not to genotype, that is the question.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing.Semantic proximity Read ↗

Point: use of pharmacogenetics in guiding treatment with warfarin.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.